Prosecution Insights
Last updated: November 04, 2026
Application No. 18/553,324

CHIMERIC NUCLEOTIDE SEQUENCE, VECTOR FOR EXPRESSION IN MAMMALS, RNA VACCINE, CHIMERIC FUSION PROTEIN, USE IN THE PRODUCTION OF A VACCINE AGAINST CORONAVIRUS

Final Rejection §103§112
Filed
Sep 29, 2023
Priority
Apr 01, 2021 — BR 10 2021 006 401-3 +1 more
Examiner
WANG, RUIXUE
Art Unit
1672
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Imunotera Soluções Terapêuticas Ltda
OA Round
2 (Final)
56%
Grant Probability
Moderate
3-4
OA Rounds
3m
Est. Remaining
76%
With Interview

Examiner Intelligence

Grants 56% of resolved cases
56%
Career Allowance Rate
68 granted / 122 resolved
-4.3% vs TC avg
Strong +20% interview lift
Without
With
+20.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
55 currently pending
Career history
185
Total Applications
across all art units

Statute-Specific Performance

§101
5.0%
-35.0% vs TC avg
§103
39.6%
-0.4% vs TC avg
§102
16.3%
-23.7% vs TC avg
§112
36.5%
-3.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 122 resolved cases

Office Action

§103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Acknowledgement is hereby made of receipt and entry of the communication filed on Aug. 06, 2026. Claims 1-5, 7-25 are pending. Claims 3-4, 5, 7 and 11-25 are withdrawn. Claims 1-2, 8-10 are currently examined. Note: the examiner called applicant and discussed the possibility of allowance with amendment for the instant application on Oct. 09, 2026. No reply is received when the Final office action is issued on Oct. 14, 2026. Drawing Objection (Previous objection- withdrawn) The drawings are objected to under 37 CFR 1.83(a). The drawings must show every feature of the invention specified in the claims. Fig. 6 filed on April 25, 2024, is difficult to read. Therefore, Fig. 6 must clearly show the sequences and labels. This objection is withdrawn in view of the amendment filed on Aug. 06, 2026. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. (Previous rejection- withdrawn) Claims 1-2, 6 and 8-10 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. This rejection is withdrawn in view of the amendment and argument filed on Aug. 06, 2026. (New rejection) Claims 1-2, 8-10 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The base claim 1 recites “the” in the phrases of “the sequences encoding…”, “the nucleotide sequence…” and “the glycoprotein D (gD)…” that renders the claims indefinite. There is insufficient antecedent basis for this limitation in the claim. Claim 2 recites “the” in the phrases of “the sequences encoding multiple different epitopes of replicase 1 ab…” in reference the base claim 1, which renders the claim indefinite because there is insufficient antecedent basis for this limitation of “replicase 1 ab” in the base claim 1. Claim 8 recites “the” in the limitation c) that render the claim indefinite. By depending on claim 1, claim 8 further comprising limitations a), b) and c), thus, it is not clear what “the nucleotide sequence ” means. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. (Previous rejection- withdrawn) Claims 1 and 2 are rejected under 35 U.S.C. 103 as being unpatentable over Almofti et al. (BMC Immunol. 2021 Mar 25;22(1):22. Hereinafter, “Almofti”, submitted in the IDS filed on 09/29/2023) as evidenced by PubChem-NCBI (https://pubchem.ncbi.nlm.nih.gov/protein/P0DTD1). This rejection is withdrawn in view of the amendment filed on Aug. 06, 2026. (Previous rejection- withdrawn) Claim 8 is rejected under 35 U.S.C. 103 as being unpatentable over Almofti et al. (BMC Immunol. 2021 Mar 25;22(1):22. Hereinafter, “Almofti”, submitted in the IDS filed on 09/29/2023) as evidenced by PubChem-NCBI (https://pubchem.ncbi.nlm.nih.gov/protein/P0DTD1) as applied to claims 1-2 above, and in view of Pereira et al. (Front Med Technol. 2020 Dec 3;2:604160, submitted in the IDS filed on 09/29/2023). This rejection is withdrawn in view of the amendment filed on Aug. 06, 2026. (Previous rejection- withdrawn) Claim 10 is rejected under 35 U.S.C. 103 as being unpatentable over Almofti et al. (BMC Immunol. 2021 Mar 25;22(1):22. Hereinafter, Almofti) as evidenced by PubChem-NCBI (https://pubchem.ncbi.nlm.nih.gov/protein/P0DTD1) as applied to claims 1-2 above, and in view of Pereira et al. (Front Med Technol. 2020 Dec 3;2:604160; submitted in IDS filed on 09/29/2023) as evidenced by Diniz et al. (Hum Gene Ther. 2013 Oct;24(10):861-70). This rejection is withdrawn in view of the amendment filed on Aug. 06, 2026. Allowable Subject Matter The nucleic acid sequence SEQ ID NOs: 97, 99 and 101 are free of prior art. Responses to Applicant’s Remarks Applicants’ arguments filed on Aug. 06, 2026, have been received and fully considered. Applicants’ amendment regarding the drawing objection is considered. The objection is withdrawn. Applicants’ amendments and arguments regarding the 112b rejections are considered. The 112b rejections are withdrawn. Applicants’ amendments regarding the 103 rejections are considered. The 103 rejections are withdrawn. Conclusion No claims are allowed. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to RUIXUE WANG whose telephone number is (571)272-7960. The examiner can normally be reached Monday-Friday 8:00 am-5:00 pm, EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Thomas J. Visone can be reached on (571) 270-0684. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /RUIXUE WANG/ Examiner, Art Unit 1672 /NICOLE KINSEY WHITE/ Primary Examiner, Art Unit 1672
Read full office action

Prosecution Timeline

Sep 29, 2023
Application Filed
May 18, 2026
Non-Final Rejection mailed — §103, §112
Aug 06, 2026
Response Filed
Oct 16, 2026
Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12758601
ONCOLYTIC ADENOVIRUS WITH REPLICATION SELECTIVITY BASED ON STATUS OF P53 TRANSCRIPTIONAL ACTIVITY
3y 9m to grant Granted Oct 13, 2026
Patent 12735754
MULTIPLEX NUCLEIC ACID DETECTION SYSTEM
4y 8m to grant Granted Sep 15, 2026
Patent 12685765
POLYPEPTIDES MIMICKING MPER AND V3-LOOP HIV-1 ENV GLYCOPROTEIN EPITOPES
2y 11m to grant Granted Jul 21, 2026
Patent 12668783
Preparation method and application of vesicle formed by erythrocyte membrane encapsulating Newcastle disease virus
3y 4m to grant Granted Jun 30, 2026
Patent 12662512
CHIMERIC POLYPEPTIDES AND USES THEREOF
4y 2m to grant Granted Jun 23, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
56%
Grant Probability
76%
With Interview (+20.1%)
3y 4m (~3m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 122 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month